Benign Conditions

Benign Hematology

Primary Immune Thrombocytopenia

Advarra IRB #H-44465/ Novartis #CVAY736Q12301 (VAYHIT2): A Phase 3 Randomized, Double-blind Study of Ianalumab (VAY736) Versus Placebo in Addition to Eltrombopag in Patients With Primary Immune Thrombocytopenia (ITP) Who Had an Insufficient Response or Relapsed After First Line Steroid Treatment (VAYHIT2)

Rheumatology

Lupus Nephritis

Central IRB #H-31578/Novartis #CYTB323-J-12201: A Phase 2, Adaptive, Randomized, Open-label, Assessor-blinded Active-controlled Study to Evaluate the Efficacy and Safety of Rapcabtagene Autoleucel Versus Standard of Care in Patients Suffering From Systemic Lupus Erythematosus (SLE) With Active, Refractory Lupus Nephritis (LN) (pending)